Get regular updates to your inbox.
Activating the JAK2-STAT3 pathway in astrocyte cells reduced multiple hallmark features of Huntington’s disease — including the toxic clumping of the huntingtin protein in nerve cells — from the brains of a mouse model, a study reported. “Our results open new therapeutic avenues to further enhance the natural partnership…
Read more
The U.S. Food and Drug Administration (FDA) has designated valbenazine an orphan drug as a potential treatment to control the involuntary, jerky movements known as chorea in people with Huntington’s disease. Orphan drug status is given to therapies with the potential to improve medical care for rare disease. It…
Clumps of protein resulting from HTT mutations, the underlying cause of Huntington’s disease, form distinct structures in different parts of the cell, according to detailed imaging analysis. The findings suggest these clumps form by different mechanisms and may require different therapeutic strategies to block their formation and toxicity that…
Columnist BJ Viau requests input from the pre-symptomatic Huntington’s disease community about the risks and benefits of clinical trials.
Click the link below to find all of the latest news related to Huntington’s disease.
Becoming educated and informed about Huntington’s disease is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your Huntington’s disease journey.
There is no cure for Huntington’s disease yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
